Global X Genomics & Biotechnology ETF $GNOM Shares Purchased by Wealth Management Partners LLC

Wealth Management Partners LLC boosted its holdings in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 143.3% during the 3rd quarter, Holdings Channel.com reports. The fund owned 24,677 shares of the company’s stock after purchasing an additional 14,533 shares during the quarter. Wealth Management Partners LLC’s holdings in Global X Genomics & Biotechnology ETF were worth $1,739,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Bank of America Corp DE lifted its holdings in shares of Global X Genomics & Biotechnology ETF by 67.8% in the first quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock valued at $5,240,000 after purchasing an additional 48,394 shares in the last quarter. Polaris Financial Partners purchased a new position in shares of Global X Genomics & Biotechnology ETF during the third quarter valued at approximately $1,067,000. Farther Finance Advisors LLC bought a new stake in Global X Genomics & Biotechnology ETF during the third quarter worth $257,000. Finally, Halbert Hargrove Global Advisors LLC bought a new stake in Global X Genomics & Biotechnology ETF during the third quarter worth $77,000. Institutional investors and hedge funds own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Trading Up 1.6%

Shares of NASDAQ:GNOM opened at $68.72 on Thursday. The stock’s fifty day simple moving average is $65.91 and its two-hundred day simple moving average is $56.06. Global X Genomics & Biotechnology ETF has a 1-year low of $41.16 and a 1-year high of $74.19. The stock has a market cap of $109.95 million, a PE ratio of -29.37 and a beta of 1.17.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.